These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 28415603)
1. Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors. Huang C; Wang W; Li Y; Zhang S; Meng F; Xu W; Yuan J; Chen L Oncotarget; 2017 Jun; 8(23):37186-37199. PubMed ID: 28415603 [TBL] [Abstract][Full Text] [Related]
2. Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation. Wang W; Yuan J; Fu X; Meng F; Zhang S; Xu W; Xu Y; Huang C Molecules; 2016 Apr; 21(4):491. PubMed ID: 27089317 [TBL] [Abstract][Full Text] [Related]
3. Identification of anthranilamide derivatives as potential factor Xa inhibitors: drug design, synthesis and biological evaluation. Xing J; Yang L; Li H; Li Q; Zhao L; Wang X; Zhang Y; Zhou M; Zhou J; Zhang H Eur J Med Chem; 2015 May; 95():388-99. PubMed ID: 25839438 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin- 4(1H)-one derivatives as potential fXa inhibitors. Xing J; Yang L; Yang Y; Zhao L; Wei Q; Zhang J; Zhou J; Zhang H Eur J Med Chem; 2017 Jan; 125():411-422. PubMed ID: 27689724 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity. Sun X; Hong Z; Liu M; Guo S; Yang D; Wang Y; Lan T; Gao L; Qi H; Gong P; Liu Y Bioorg Med Chem; 2017 May; 25(10):2800-2810. PubMed ID: 28389110 [TBL] [Abstract][Full Text] [Related]
6. Advances in the Development of Novel Factor Xa Inhibitors: A Patent Review. Khadse AN; Sharma MK; Murumkar PR; Rajput SJ; Yadav MR Mini Rev Med Chem; 2018; 18(16):1332-1353. PubMed ID: 29692238 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors. Xing J; Yang L; Zhou J; Zhang H Bioorg Med Chem; 2018 Dec; 26(23-24):5987-5999. PubMed ID: 30446438 [TBL] [Abstract][Full Text] [Related]
9. Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants? Papadaki S; Tselepis AD Angiology; 2019 Nov; 70(10):896-907. PubMed ID: 31010298 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of Isosteviol derivatives as FXa inhibitors. Shi Y; Pan BW; Li WC; Wang Q; Wu Q; Pan M; Fu HZ Bioorg Med Chem Lett; 2020 Jan; 30(2):126585. PubMed ID: 31859158 [TBL] [Abstract][Full Text] [Related]
11. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding. Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063 [TBL] [Abstract][Full Text] [Related]
12. Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity. Wiley MR; Weir LC; Briggs S; Bryan NA; Buben J; Campbell C; Chirgadze NY; Conrad RC; Craft TJ; Ficorilli JV; Franciskovich JB; Froelich LL; Gifford-Moore DS; Goodson T; Herron DK; Klimkowski VJ; Kurz KD; Kyle JA; Masters JJ; Ratz AM; Milot G; Shuman RT; Smith T; Smith GF; Tebbe AL; Tinsley JM J Med Chem; 2000 Mar; 43(5):883-99. PubMed ID: 10715155 [TBL] [Abstract][Full Text] [Related]
13. Synthesis of 3,4-diaminobenzoyl derivatives as factor Xa inhibitors. Yang J; Su G; Ren Y; Chen Y Eur J Med Chem; 2015 Aug; 101():41-51. PubMed ID: 26114810 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and Thrombin, Factor Xa and U46619 Inhibitory Effects of Non-Amidino and Amidino N²-Thiophenecarbonyl- and N²-Tosylanthranilamides. Lee SH; Lee W; Nguyen T; Um IS; Bae JS; Ma E Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561744 [TBL] [Abstract][Full Text] [Related]
15. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches. Bhunia SS; Roy KK; Saxena AK J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and structure-activity relationship of oxazolidinone derivatives containing novel S4 ligand as FXa inhibitors. Zhao Y; Jiang M; Zhou S; Wu S; Zhang X; Ma L; Zhang K; Gong P Eur J Med Chem; 2015; 96():369-80. PubMed ID: 25911624 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationship of potent, selective and orally active anthranilamide-based factor Xa inhibitors: application of weakly basic sulfoximine group as novel S4 binding element. Pandya V; Jain M; Chakrabarti G; Soni H; Parmar B; Chaugule B; Patel J; Jarag T; Joshi J; Joshi N; Rath A; Unadkat V; Sharma B; Ajani H; Kumar J; Sairam KV; Patel H; Patel P Eur J Med Chem; 2012 Dec; 58():136-52. PubMed ID: 23124211 [TBL] [Abstract][Full Text] [Related]
18. Surfing the Blood Coagulation Cascade: Insight into the Vital Factor Xa. Núñez-Navarro NE; Santana FM; Parra LP; Zacconi FC Curr Med Chem; 2019; 26(17):3175-3200. PubMed ID: 29376487 [TBL] [Abstract][Full Text] [Related]
19. Identification of AcAP5 as a novel factor Xa inhibitor with both direct and allosteric inhibition. Zhu Y; Lin Y; Liu X; Hu W; Wang Y Biochem Biophys Res Commun; 2017 Jan; 483(1):495-501. PubMed ID: 28007598 [TBL] [Abstract][Full Text] [Related]
20. Effect of SanOrg123781A, a synthetic hexadecasaccharide, on clot-bound thrombin and factor Xa in vitro and in vivo. Hérault JP; Cappelle M; Bernat A; Millet L; Bono F; Schaeffer P; Herbert JM J Thromb Haemost; 2003 Sep; 1(9):1959-65. PubMed ID: 12941037 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]